Article
Oncology
Beth Russell, Charlotte L. Moss, Kieran Palmer, Rushan Sylva, Andrea D'Souza, Harriet Wylie, Anna Haire, Fidelma Cahill, Renee Steel, Angela Hoyes, Isabelle Wilson, Alyson Macneil, Belul Shifa, Maria J. Monroy-Iglesias, Sophie Papa, Sheeba Irshad, Paul Ross, James Spicer, Shahram Kordasti, Danielle Crawley, Kamarul Zaki, Ailsa Sita-Lumsden, Debra Josephs, Deborah Enting, Angela Swampillai, Elinor Sawyer, Paul Fields, David Wrench, Anne Rigg, Richard Sullivan, Mieke Van Hemelrijck, Saoirse Dolly
Summary: The study found that male, Black or Asian ethnicity, and patients with hematological malignancies are at an increased risk of COVID-19. Using cancer patients as the COVID-19 negative comparator group is a major advantage to the study, helping better understand the true impact of COVID-19 on cancer patients.
Article
Oncology
Nikolai Klebanov, Vartan Pahalyants, William S. Murphy, Nicholas Theodosakis, Leyre Zubiri, R. Monina Klevens, Shawn G. Kwatra, Evelyn Lilly, Kerry L. Reynolds, Yevgeniy R. Semenov
Summary: The study aimed to determine the rate of COVID-19 among cancer patients treated with immune checkpoint inhibitors (ICIs). Results showed that there was no significant increase in COVID-19 susceptibility in the ICI group compared to controls. This information may help patients and oncologists make decisions about cancer treatment during the pandemic.
Article
Oncology
Manju Sengar, Girish Chinnaswamy, Priya Ranganathan, Apurva Ashok, Shilpushp Bhosale, Sanjay Biswas, Pankaj Chaturvedi, Chetan Dhamne, Jigeeshu Divatia, Karishma D'Sa, Hasmukh Jain, Sarbani Laskar, Nirmalya Roy Moulik, Naveen Mummudi, Sindhu Nair, Lingaraj Nayak, Prakash Nayak, Shraddha Patkar, Preeti Pawaskar, Anant Ramaswamy, Omshree Shetty, Arjun Singh, Epari Sridhar, Jayashree Thorat, Rajendra Badwe, C. S. Pramesh
Summary: Pramesh and colleagues conducted a study on the risk factors and outcomes in cancer patients infected with SARS-CoV-2 in India. They found that cancer patients are at higher risk for severe COVID-19. Advancing age, smoking history, concurrent comorbidities, and palliative intent of treatment were independently associated with severe COVID-19 or death.
Article
Oncology
Hitomi Suzuki, Tomohiro Akiyama, Nobuko Ueda, Satoko Matsumura, Miki Mori, Masatoshi Namiki, Norikazu Yamada, Chika Tsutsumi, Satoshi Tozaki, Hisayuki Iwamoto, Shun Torii, Yuichiro Okubo, Kiyosuke Ishiguro
Summary: Cancer patients are concerned about the effects of the COVID-19 vaccination. Consulting with a physician can alleviate their concerns and encourage vaccination.
Article
Oncology
Junnan Liang, Guannan Jin, Tongtong Liu, Jingyuan Wen, Ganxun Li, Lin Chen, Wei Wang, Yuwei Wang, Wei Liao, Jia Song, Zeyang Ding, Xiao-ping Chen, Bixiang Zhang
Summary: Cancer patients have a higher risk of COVID-19 infection and poorer prognosis compared to non-cancer patients. High-risk tumor, NRS2002 score > 3, advanced tumor stage, and recent adjuvant therapy (< 1 month) may be independent risk factors for in-hospital death among cancer patients.
FRONTIERS OF MEDICINE
(2021)
Review
Infectious Diseases
Magda Palka-Kotlowska, Sara Custodio-Cabello, Eduardo Oliveros-Acebes, Parham Khosravi-Shahi, Luis Cabezon-Gutierrez
Summary: This study found a significant association between household exposure and seroconversion risk for cancer patients, highlighting the need for implementing recommendations to prevent virus transmission in household settings.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
Pin Li, Wei Zhao, Scott Kaatz, Katie Latack, Lonni Schultz, Laila Poisson
Summary: This cohort study of 2832 adult patients hospitalized with COVID-19 found a decreased risk of venous thromboembolism over time after discharge, while no change was observed in the risk of arterial thromboembolism with time. Patients with a history of venous thromboembolism, peak D-dimer level greater than 3 ug/mL, and predischarge C-reactive protein level greater than 10 mg/dL were more likely to experience venous thromboembolism after discharge. However, therapeutic anticoagulation prescriptions at discharge were associated with reduced incidence of venous thromboembolism.
Article
Immunology
Ellinor Peerschke, Alisa Valentino, Rachel J. So, Scott Shulman, Ravinder
Summary: The study found that cancer patients with COVID-19 exhibit circulating markers of endothelial cell dysfunction, platelet activation, and systemic inflammation. Furthermore, complement activation in cancer patients with COVID-19 increases significantly in the presence of thromboinflammation, indicating a possible link between coagulation and complement cascades during inflammation.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Gastroenterology & Hepatology
Jasmohan S. Bajaj, Guadalupe Garcia-Tsao, Scott W. Biggins, Patrick S. Kamath, Florence Wong, Sara McGeorge, Jawaid Shaw, Meredith Pearson, Micheal Chew, Andrew Fagan, Randolph de la Rosa Rodriguez, Janelle Worthington, Amy Olofson, Vanessa Weir, Calvin Trisolini, Sarah Dwyer, K. Rajender Reddy
Summary: Patients with cirrhosis and COVID-19 had higher mortality compared with patients with COVID-19 alone, but similar mortality compared with patients with cirrhosis alone. Charlson Comorbidity Index (CCI) was the only independent predictor of mortality in the entire matched cohort.
Article
Hematology
Ang Li, Nicole M. Kuderer, Chih-Yuan Hsu, Yu Shyr, Jeremy L. Warner, Dimpy P. Shah, Vaibhav Kumar, Surbhi Shah, Amit A. Kulkarni, Julie Fu, Shuchi Gulati, Rebecca L. Zon, Monica Li, Aakash Desai, Pamela C. Egan, Ziad Bakouny, K. C. Devendra, Clara Hwang, Imo J. Akpan, Rana R. McKay, Jennifer Girard, Andrew L. Schmidt, Balazs Halmos, Michael A. Thompson, Jaymin M. Patel, Nathan A. Pennell, Solange Peters, Amro Elshoury, Gilbero de Lima Lopes, Daniel G. Stover, Petros Grivas, Brian Rini, Corrie A. Painter, Sanjay Mishra, Jean M. Connors, Gary H. Lyman, Rachel P. Rosovsky
Summary: Hospitalized patients with cancer and COVID-19 are at increased risk of VTE and ATE. A simplified RAM model named CoVID-TE was developed to predict VTE in this vulnerable population, showing good performance in stratifying patients into low-risk and high-risk cohorts based on clinical risk factors. The CoVID-TE RAM may aid in real-time data-driven decisions for thrombosis prevention in this population.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Biology
Issam I. Raad, Ray Hachem, Nigo Masayuki, Tarcila Datoguia, Hiba Dagher, Ying Jiang, Vivek Subbiah, Bilal Siddiqui, Arnaud Bayle, Robert Somer, Ana Fernandez Cruz, Edward Gorak, Arvinder Bhinder, Nobuyoshi Mori, Nelson Hamerschlak, Samuel Shelanski, Tomislav Dragovich, Yee Elise Vong Kiat, Suha Fakhreddine, Abi Hanna Pierre, Roy F. Chemaly, Victor Mulanovich, Javier Adachi, Jovan Borjan, Fareed Khawaja, Bruno Granwehr, Teny John, Eduardo Yepez Yepez, Harrys A. Torres, Natraj Reddy Ammakkanavar, Marcel Yibirin, Cielito C. Reyes-Gibby, Mala Pande, Noman Ali, Raniv Dawey Rojo, Shahnoor M. Ali, Rita E. Deeba, Patrick Chaftari, Takahiro Matsuo, Kazuhiro Ishikawa, Ryo Hasegawa, Ramon Aguado-Noya, Alvaro Garcia Garcia, Cristina Traseira Puchol, Dong Gun Lee, Monica Slavin, Benjamin Teh, Cesar A. Arias, Dimitrios P. Kontoyiannis, Alexandre E. Malek, Anne-Marie Chaftari
Summary: This international multicenter study aimed to identify independent risk factors for increased 30-day mortality in COVID-19 patients with and without cancer. The study analyzed data from 16 international centers and found that cancer itself was not an independent risk factor for increased mortality. Older age and lymphopenia were the main predictors of 30-day mortality in all patients, and remdesivir was the only therapeutic agent associated with decreased mortality.
Article
Immunology
Georgios Chamilos, Michail S. Lionakis, Dimitrios P. Kontoyiannis
Summary: Not all cancer patients are equally at risk for severe COVID-19 complications, as factors other than cancer or its treatment may play a significant role. Further research is needed to understand the impact of COVID-19 on this heterogeneous population of patients.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Oncology
Lisa A. Newman, Robert A. Winn, John M. Carethers
Summary: COVID-19 disproportionately affects racial and ethnic minorities in the United States, particularly African Americans, with higher rates of hospitalization and death compared to White Americans. This disparity is consistent with patterns observed for cancer disparities, with overlapping root causes contributing to both diseases.
CLINICAL CANCER RESEARCH
(2021)
Article
Clinical Neurology
Irene Moreno-Torres, Virginia Meca Lallana, Lucienne Costa-Frossard, Celia Oreja-Guevara, Clara Aguirre, Elda Maria Alba Suarez, Mayra Gomez Moreno, Laura Borrega Canelo, Julia Sabin Munoz, Yolanda Aladro, Alba Carcamo, Elena Rodriguez Garcia, Juan Pablo Cuello, Enric Monreal, Susana Sainz de la Maza, Fernando Perez Parra, Francisco Valenzuela Rojas, Carlos Lopez de Silanes de Miguel, Ignacio Casanova, Maria Luisa Martinez Gines, Rosario Blasco, Aida Orviz Garcia, Luisa Maria Villar-Guimerans, Guillermo Fernandez-Dono, Victor Elvira, Carmen Santiuste, Mercedes Espino, Jose Manuel Garcia Dominguez
Summary: This study found that patients with multiple sclerosis do not have a higher risk of SARS-CoV-2 infection or severe COVID-19 outcomes compared to the general population, but they do have higher hospitalization rates. In the study, males with MS had higher incidence rates and risk of hospitalization than females.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Article
Oncology
Astha Thakkar, Jesus D. Gonzalez-Lugo, Niyati Goradia, Radhika Gali, Lauren C. Shapiro, Kith Pradhan, Shafia Rahman, So Yeon Kim, Brian Ko, R. Alejandro Sica, Noah Kornblum, Lizamarie Bachier-Rodriguez, Margaret McCort, Sanjay Goel, Roman Perez-Soler, Stuart Packer, Joseph Sparano, Benjamin Gartrell, Della Makower, Yitz D. Goldstein, Lucia Wolgast, Amit Verma, Balazs Halmos
Summary: Most cancer patients show high seroconversion rates after receiving COVID-19 vaccines, but those with hematologic malignancies, especially after highly immunosuppressive therapies, exhibit lower conversion rates. Patients on immune checkpoint inhibitor therapy or hormonal therapy display high conversion rates.
